Background: Breastfeeding and postpartum contraception critically influence infant and maternal health outcomes. In this pilot study, we explore the effects of timing and duration of postpartum levonorgestrel exposure on milk lipid and levonorgestrel content to establish baseline data for future research.
Methods: This sub-study recruited a balanced convenience sample from 259 participants enrolled in a parent randomized controlled trial comparing immediate to delayed (4-8 weeks) postpartum levonorgestrel IUD placement. All planned to breastfeed, self-selected for sub-study participation, and provided the first sample at 4-8 weeks postpartum (before IUD placement for the delayed group) and the second four weeks later. We used the Wilcoxon rank sum (inter-group) and signed rank (intra-group) tests to compare milk lipid content (creamatocrit) and levonorgestrel levels between groups and time points.
Results: We recruited 15 participants from the immediate group and 17 from the delayed group with 10 and 12, respectively, providing both early and late samples. Initially, median levonorgestrel concentration of the immediate group (n = 10) (32.5 pg/mL, IQR: 24.8, 59.4) exceeded that of the delayed group (n = 12) (17.5 pg/mL, IQR: 0.0, 25.8) (p = 0.01). Four weeks later, the values aligned: 26.2 pg/mL (IQR: 20.3, 37.3) vs. 28.0 pg/mL (IQR: 25.2, 40.8). Creamatocrits were similar between both groups and timepoints.
Conclusions: Immediate postpartum levonorgestrel IUD placement results in steady, low levels of levonorgestrel in milk without apparent effects on lipid content. These findings provide initial support for the safety of immediate postpartum levonorgestrel IUD initiation, though the study was not powered to detect noninferiority between groups.
Trial Registration: This randomized controlled trial was registered with ClinicalTrials.gov (Registry No. NCT01990703) on November 21, 2013.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818753 | PMC |
http://dx.doi.org/10.1186/s12905-021-01179-7 | DOI Listing |
J Am Board Fam Med
January 2025
From the University of Missouri, Columbia, MO (SHM, CT, LM).
Counsel patients that their Mirena IUD retains contraceptive effectiveness for extended use up to 8 years. The cumulative failure rate for years 6 through 8 was 0.68%, similar to reported rates for the first 5 years of use.
View Article and Find Full Text PDFArch Gynecol Obstet
December 2024
Department of Obstetrics and Gynecology, Odense University Hospital, Kløvervænget 23, 5000, Odense, Denmark.
Objective: Endometrial resection and ablation are minimal invasive surgeries used to treat women with abnormal uterine bleeding (AUB). Both may be followed by a high reoperation rate up to 24%. However, some studies suggest that this may be improved by adding a levonorgestrel intrauterine device (LNG-IUD) immediately following surgery.
View Article and Find Full Text PDFJ Pediatr Adolesc Gynecol
December 2024
Children's Minnesota Department of Pediatric and Adolescent Gynecology.
Background: Levonorgestrel intrauterine devices (IUDs) provide effective contraception and medical benefits. They are safe for even severely medically complex patients. The CDC Medical Eligibility Criteria (MEC) states IUDs are category 4 for people with uterine cavity distortions, however there are previous case reports of their successful use in this population.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
December 2024
Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil.
Objective: Emergency contraception serves as the only dependable method for women to prevent pregnancy following unprotected sex. Among emergency contraception methods, the copper intrauterine device provides continuous, highly effective contraception for over a decade. This study aimed to evaluate the effectiveness, safety, and side effects of the copper intrauterine device over methods containing levonorgestrel for emergency contraception.
View Article and Find Full Text PDFEClinicalMedicine
December 2024
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Background: Globally, approximately 19.4% of women of reproductive age use intrauterine contraception, encompassing both copper intrauterine devices (Cu-IUDs) and levonorgestrel intrauterine devices (LNG-IUDs). Despite current guidelines endorsing intrauterine contraception as a primary method, there remains debate regarding device selection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!